MTOR and acute myeloid leukemia: Surprisingly, the addition of the well-known autophagy-stimulating mTOR inhibitors was not sufficient to induce autophagy as long as the β-Catenin level was stable.3 Resistances of AML patients to mTOR inhibitors and their low clinical benefit have already been moaned.12 On the basis of their observations, Kühn et al. proposed that high β-Catenin expression was responsible for this resistance, which can be circumvented by the application of LecB.